Welcome to our dedicated page for XOMA Royalty SEC filings (Ticker: XOMAP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on XOMA Royalty's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into XOMA Royalty's regulatory disclosures and financial reporting.
Maricel P. Montano, Chief Legal Officer and Director of XOMA Royalty Corp (XOMA), reported insider transactions dated 09/19/2025. The filing shows acquisition of 3,033 Performance Stock Units (PSUs) and 3,033 shares of Common Stock recorded as acquired with $0 price, with PSUs vesting upon the company's common stock reaching a specified price per share. After the reported transactions the filing lists 12,134 shares of common stock and 11,316 derivative units beneficially owned following the transactions. The PSUs have a stated date exercisable of 05/18/2026 per the filing. The Form 4 was signed by an attorney-in-fact on behalf of Ms. Montano on 09/23/2025.
XOMA Royalty Corporation (XOMAP) entered into a merger with HilleVax, Inc. under an Agreement and Plan of Merger dated August 4, 2025, after a related tender offer described in an Offer to Purchase dated August 18, 2025. At the Effective Time, Merger Sub merged into HilleVax and HilleVax became a wholly owned subsidiary of XOMA, with outstanding HilleVax shares (subject to customary exceptions) cancelled and converted into the right to receive the Offer Price, comprised of a cash amount and a non-transferable Contingent Value Right (CVR).
A Contingent Value Rights Agreement dated September 17, 2025 governs potential cash payments under the CVR, with Broadridge named as rights agent and Dr. Robert Hershberg as initial representative of holders. The filing attaches the Merger Agreement, the CVR Agreement, and a press release incorporated by reference.
XOMA Royalty Corporation completed a merger with Turnstone Biologics Corp. under an Agreement and Plan of Merger dated June 26, 2025, effected by a merger of XOMA's wholly owned subsidiary into Turnstone under Delaware law with no stockholder vote required. At the Effective Time, each outstanding share (subject to limited exceptions) was converted into the right to receive a cash payment equal to the Cash Amount (less tax withholding) and one CVR governed by the Contingent Value Rights Agreement dated August 11, 2025. The CVR entitles holders to potential additional cash payments under specified terms, and the Offer to Purchase and Letter of Transmittal were filed as exhibits to the Schedule TO on July 23, 2025. The filing attaches the Merger Agreement, the CVR Agreement, and a press release incorporated by reference.
XOMA Royalty Corp. reporting person Maricel Perea Montano, Chief Legal Officer and director, was granted 23,450 Performance Stock Units (PSUs) on 08/12/2025. Each PSU converts to one share of XOMA common stock if a specified stock price target is met. The PSUs are shown as acquired with a $0 exercise price and are recorded as 23,450 shares beneficially owned following the award, held in a direct form.
The PSUs become eligible for issuance on 05/16/2026 subject to achieving the stated price condition. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person on 08/14/2025. No sale or cash payment is reported; this filing documents a contingent equity award tied to future stock performance.
Maricel P. Montano is identified as Chief Legal Officer and a director-level reporting person for XOMA Royalty Corp (XOMAP). The Form 3 dated 08/12/2025 indicates no securities are beneficially owned by the reporting person. The submission was signed on behalf of Montano by an attorney-in-fact, Thomas Burns, on 08/14/2025. This filing is an initial ownership statement showing the officer/director relationship but reporting no direct or indirect holdings.
XOMA Royalty Corporation filed a Current Report announcing it issued a press release that reports the company's financial results for the fiscal quarter ended June 30, 2025. The filing states the full text of that press release is attached as Exhibit 99.1 and is incorporated by reference into the report.
The Form also notes that the information in the Form and the attached Exhibit is not to be deemed filed for purposes of Section 18 of the Exchange Act and is not incorporated by reference in other filings except as expressly stated. The Form itself does not present financial figures; readers must consult Exhibit 99.1 for the results and highlights.
XOMA Royalty Corporation is a biotech royalty aggregator, recently reincorporated to Nevada in May 2025. As of June 30, 2025 total assets were $223,456 thousand and total unrestricted and restricted cash and cash equivalents were $78,485 thousand. Management concluded its cash balance is sufficient to fund planned operations, commitments, and contractual obligations for at least one year.
For the three months ended June 30, 2025 total income and revenues were $13,129 thousand and net income was $9,191 thousand, compared with net income of $15,985 thousand in the prior-year quarter. For the six months ended June 30, 2025 total income and revenues were $29,041 thousand and net income was $11,558 thousand. Income from operations was $4,603 thousand for the quarter versus an operating loss of $10,079 thousand in the comparable prior quarter. Stockholders' equity increased to $72,435 thousand from $61,902 thousand at December 31, 2024.
The company paid $20,614 thousand for a BioInvent contract-based intangible asset during the period, recorded long-term debt of $102,201 thousand and convertible preferred stock of $20,019 thousand. The Company reclassified its Series X Convertible Preferred Stock as mezzanine (temporary) equity and restated comparative balances, which management judged immaterial.